455 Mission Bay Blvd South
About Nektar Therapeutics
Nektar Therapeutics is a research-based development stage biopharmaceutical company that discovers and develops innovative medicines in areas of high unmet medical need. Our R&D pipeline of new investigational drugs includes treatments for cancer and auto-immune disease. We leverage Nektar's proprietary and proven chemistry platform in the discovery and design of our new drug candidates. Our success is rooted in four key elements: our track record reflected by a portfolio of successful approved medicines which emanated from our chemistry platform and are made available globally by our pharmaceutical partners, our unique research and development pipeline of new investigational medicines in cancer and immunology, our proprietary and proven science and technology approach that fuels our discovery efforts and our team of dedicated scientists, clinicians and employees focused on bringing new medicines to patients with debilitating diseases.
Stock Symbol: NKTR
Stock Exchange: NASDAQ
473 articles about Nektar Therapeutics
Nektar Therapeutics Announces Promising New Data from Phase 1b Study of Rezpegaldesleukin in Moderate-to-Severe Atopic Dermatitis
Nektar Therapeutics (Nasdaq: NKTR) today announced new data for rezpegaldesleukin in patients with atopic dermatitis, including new clinical efficacy endpoints from the Phase 1b study. Rezpegaldesleukin is Nektar's novel, first-in-class selective regulatory T-cell (Treg) therapy, which is being developed for the treatment of atopic dermatitis.
Nektar Therapeutics to Host Virtual Investor & Analyst Event with Dermatology Experts on September 13th
Nektar Therapeutics (Nasdaq: NKTR) today announced that it will host a virtual investor and analyst event on Wednesday, September 13, 2023 at 11:00 a.m. EST / 8:00 a.m. PST to discuss the final Phase 1b data of rezpegaldesleukin (REZPEG) in patients with atopic dermatitis, the atopic dermatitis treatment landscape, and the potential role of REZPEG, Nektar's novel, first-in-class selective regulatory T-cell (Treg) therapy, in the treatment of atopic dermatitis.
Week in Review: Novo Nordisk Riding High, Novavax in the Black (For Now), Nektar Sues Lilly and More
8/11/2023Novo’s weight-loss drug Wegovy improves cardiovascular outcomes, Novavax posts surprise Q2 profit, while Nektar Therapeutics files lawsuit against Eli Lilly for misconduct in drug development deal.
Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the second quarter ended June 30, 2023.
In a lawsuit filed Monday, Nektar Therapeutics accused Eli Lilly of scheming to ensure rezpegaldesleukin would not succeed after acquiring a competing medicine.
Nektar Announces Promising New and Corrected Rezpegaldesleukin Efficacy Data Which Were Previously Reported in 2022 and Incorrectly Calculated by Former Collaborator Eli Lilly & Company
Nektar Therapeutics announced that efficacy data previously generated by Eli Lilly & Company for rezpegaldesleukin that were presented at the September 2022 EADV Congress were incorrectly calculated by Lilly.
Nektar to Announce Financial Results for the Second Quarter 2023 on Tuesday, August 8, 2023, After Close of U.S.-Based Financial Markets
Nektar Therapeutics will announce its financial results for the second quarter 2023 on Tuesday, August 8, 2023, after the close of U.S.-based financial markets.
Nektar Therapeutics to Participate in Fireside Chat at the Goldman Sachs 44th Annual Global Healthcare Conference
Nektar Therapeutics' senior management is scheduled to participate in a virtual fireside chat at the upcoming Goldman Sachs 44th Annual Global Healthcare Conference on Wednesday, June 14, 2023 at 1:20 p.m. Pacific Time.
Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the first quarter ended March 31, 2023.
Nektar Therapeutics Announces It Will Regain Full Rights to Rezpegaldesleukin (REZPEG, NKTR-358), a Novel, First-in-Class Selective Regulatory T-cell (Treg) Therapy in Clinical Development
Nektar Therapeutics (Nasdaq: NKTR) today announced that it will be regaining the full rights to REZPEG from Eli Lilly and Company.
Nektar Therapeutics announced a strategic reprioritization and cost restructuring plan that includes a new pipeline focus on immunology, as well as several cost reduction initiatives, which the company expects will significantly reduce future operating expenses and extend its cash runway into the middle of 2026.
Nektar Therapeutics Issues Statement Confirming That It Does Not Hold Any Cash Deposits or Securities at Silicon Valley Bank
Nektar Therapeutics issued a statement confirming that it does not have any accounts at Silicon Valley Bank, and it does not hold any cash deposits or securities at Silicon Valley Bank.
Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the fourth quarter and full year ended December 31, 2022.
Rezpegaldesleukin, Lilly’s and Nektar Therapeutics’ candidate for systemic lupus erythematosus, fell short of its primary efficacy endpoint in the Phase II ISLAND trial.
Nektar Therapeutics Announces Phase 2 Topline Data for Rezpegaldesleukin in Patients with Systemic Lupus Erythematosus
Nektar Therapeutics (Nasdaq: NKTR) today announced topline data from a Phase 2 randomized, double-blind, placebo-controlled study of rezpegaldesleukin.
Nektar Therapeutics' President and CEO, Howard Robin, To Present at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco, CA
Nektar Therapeutics' President and Chief Executive Officer, Howard Robin, is scheduled to present at the upcoming 41st Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 11, 2023 at 8:15 a.m. Pacific Time.
Nektar Announces Poster Presentations at the 64th American Society of Hematology (ASH) Annual Meeting
Nektar Therapeutics (Nasdaq: NKTR) today announced two presentations of NKTR-255 at the 64th American Society of Hematology (ASH) Annual Meeting.
Nektar Therapeutics (Nasdaq: NKTR) today announced that it will host an investor and analyst event on Monday, December 12, 2022 at 7:30 a.m. CST.
Nektar Therapeutics Presents Preclinical Data from Novel PEGylated Interferon Gamma Program, NKTR-288, at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
Nektar Therapeutics (Nasdaq: NKTR) today announced the first presentation of preclinical data for NKTR-288 at the 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting.
Nektar and Collaborators Announce Publication in Blood Advances of Preclinical Data Demonstrating NKTR-255, a Novel Polymer-conjugated Human IL-15, Improves Efficacy of CD19-targeted CAR-T Cell Immunotherapy
Nektar Therapeutics (Nasdaq: NKTR) today announced the publication of preclinical data in Blood Advances, the open-access journal of the American Society of Hematology, highlighting the effects of NKTR-255 on the efficacy of human CD19 CAR-T cells in a xenogeneic lymphoma model and on CD8+ T effector cell (Tcell) and natural killer (NK) cell proliferation in non-human primates.